We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-2.14%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$93.7M
AUM Growth
-$14.2M
Cap. Flow
-$5.83M
Cap. Flow %
-6.22%
Top 10 Hldgs %
66.44%
Holding
48
New
3
Increased
5
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
TRML
Tourmaline Bio
TRML
+$2.02M
2
MRUS
Merus
MRUS
+$1.48M
3
ZLAB icon
Zai Lab
ZLAB
+$967K
4
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$519K
5
BCYC
Bicycle Therapeutics
BCYC
+$391K

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.5M
2
NMRA icon
Neumora Therapeutics
NMRA
+$871K
3
ILMN icon
Illumina
ILMN
+$374K
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$187K
5
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$85.9K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LONA
26
LeonaBio Inc
LONA
$72.1M
$477K 0.51%
18,000
– –
PACB icon
27
Pacific Biosciences
PACB
$370M
$376K 0.4%
274,488
– –
CABA icon
28
Cabaletta Bio
CABA
$455M
$353K 0.38%
47,150
– –
BCYC
29
Bicycle Therapeutics
BCYC
$292M
$350K 0.37%
+17,300
New +$391K
ROIV icon
30
Roivant Sciences
ROIV
$26.2B
$343K 0.37%
32,470
– –
KYMR icon
31
Kymera Therapeutics
KYMR
$8.94B
$325K 0.35%
10,875
– –
GRAL
32
GRAIL Inc
GRAL
$3.1B
$305K 0.33%
+19,866
New +$322K
RVMD icon
33
Revolution Medicines
RVMD
$44B
$283K 0.3%
7,300
– –
SWTX
34
DELISTED
SpringWorks Therapeutics
SWTX
$281K 0.3%
7,450
– –
ALXO icon
35
ALX Oncology
ALXO
$290M
$253K 0.27%
41,950
– –
IMCR icon
36
Immunocore
IMCR
$1.73B
$229K 0.24%
6,750
– –
AFMD
37
DELISTED
Affimed
AFMD
$203K 0.22%
37,247
– –
IMTX icon
38
Immatics
IMTX
$1.32B
$182K 0.19%
15,700
– –
BMEA icon
39
Biomea Fusion
BMEA
$91.3M
$180K 0.19%
40,000
– –
ABCL icon
40
AbCellera Biologics
ABCL
$2.12B
$151K 0.16%
50,971
– –
DBVT
41
DBV Technologies
DBVT
$847M
$149K 0.16%
37,095
– –
JBIO
42
Jade Biosciences
JBIO
$1.34B
$79.6K 0.08%
1,370
– –
KOD icon
43
Kodiak Sciences
KOD
$2.84B
$75K 0.08%
31,922
– –
KYNB
44
Kyntra Bio
KYNB
$29.4M
$55.4K 0.06%
2,484
– –
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$2.4B
– –
-36,847
Closed -$187K
NMRA icon
46
Neumora Therapeutics
NMRA
$302M
– –
-63,315
Closed -$871K
GRTX
47
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
– –
-613,223
Closed -$85.9K
ALPN
48
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-263,940
Closed -$10.5M
1
2

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q2 2024 Portfolio in Review

As of Q2 2024, Nan Fung Group Holdings held 48 positions worth $93.7M, down 13% from $108M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Nan Fung Group Holdings withdrew a net $5.83M in Q2 2024, closing 4 positions and reducing 1 holding. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Nan Fung Group Holdings opened a new position in Zai Lab worth $953K.

  • Nan Fung Group Holdings's largest Q2 2024 buy was Zai Lab: 55,000 shares worth $953K.
  • Nan Fung Group Holdings added most to Tourmaline Bio in Q2 2024, an estimated $2.02M increase.
  • Nan Fung Group Holdings's biggest Q2 2024 reduction was Illumina, cutting an estimated $374K.
  • Nan Fung Group Holdings fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.5M.
  • Nan Fung Group Holdings's ten largest holdings make up 66% of its $93.7M portfolio in Q2 2024.
  • Nan Fung Group Holdings opened 3 new positions and closed 4 in Q2 2024.
  • Nan Fung Group Holdings's portfolio value fell 13% quarter-over-quarter to $93.7M.

Based on Nan Fung Group Holdings's 13F filing for Q2 2024, filed 13 Aug 2024.